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INTRODUCTION
Zinc oxide (ZnO) is a semiconductor material and is applied in
light-emitting devices (1) and electron emitters (2). ZnO nano-
particles (NPs) have been widely used in various commercial prod-
ucts such as sensors, electronics, antibacterial reagents, rubber
additives, paints, pigments, cosmetics, and food additives (3). ZnO
is suitable for bio- imaging applications because it has a wide band
gap (Eg=3.37 eV) with a large excitation binding energy (60 eV)
and ensures efficient UV-blue emission at room temperature (4).
Zn is an essential element, and ZnO is less toxic than quantum dot,
which contains Cd. Therefore, application of ZnO NPs are expected
to apply to cancer diagnosis and therapy, used as drug delivery
carriers. Senthilkumar et al. have reported good quality ZnO NPs
that disperse in water and organic solvents by a different surface
treatment procedure for biomedical applications (5). Sato et al.
have successfully prepared non-cytotoxic and visible light-emitting
ZnO NP fluorophores as probes with binding sites to biomolecules
on the surface for biological imaging (6, 7). However, no data is
available on the toxicity of these materials in vivo .
Recently, with the increasing attention that has been paid to
nanotoxicity, several studies have reported the toxicity of ZnO NPs
in vivo : intranasal instillation (8), intratracheal instillation (9), and
oral administration (10), dermal exposure (11). In order to apply
to bio- imaging, toxicity evaluation following intravenous admini-
stration needs to be performed. To our knowledge, no information
is available on ZnO NP toxicity following intravenous administra-
tion. Moreover, the toxicological mechanism and tissue distribution
of ZnO NPs have not yet been systematically studied following
intravenous injection. In the present study, the blood kinetics and
tissue distribution of a toxic dose of ZnO NPs were investigated
up to 6 days after intravenous exposure. The toxicity of ZnO NPs
have shown to be related to oxidative stress, lipid peroxidation, cell
membrane leakage, and oxidative DNA damage in vitro (12, 13).
In the present study, 8-hydroxy-2’ -deoxyguanosine (8-OHdG),
commonly used as a marker for oxidative stress (14), was evalu-
ated following intravenous ZnO NPs injection.
MATERIALS AND METHODS
Materials
ZnO dispersion NPs,100 nm particle size (DLS),35 nm
avg. part. size (APS), 50 wt. % in H2O (Modification type : cat-
ionic - 3 -Aminopropyl triethoxysilane) was purchased from Sigma-
Aldrich (St. Lous, MO, USA). Before intravenous administration,
the dispersion was diluted with distilled water to prevent aggre-
gation.
Animals
Eight-week-old female ICR mice (B.W. 27.0-34.2 g) were pur-
chased from CLEA Japan, Incorporated (Tokyo, Japan). The mice
were housed two to a cage in a 12 h light/dark cycle with unlimited
access to mouse chow and water. They were allowed to acclimate
to their environment for 1 week before treatment. In a preliminary
experiment, gender difference was not observed regarding ZnO
NPs. These mice received a single intravenous dose via the tail vein
at 1 ml/kg body weight (0.027 ml-0.034 ml). The experimental
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protocols were approved by the Shimane University Animal Ex-
perimental Committee.
LD50 estimation
LD50 estimation was carried out using the Litchfield-Wilcoxon
method (15). A total of 65 mice were exposed to 500, 50, 5, 0.5,
0.4, 0.38, 0.36, 0.34, 0.33, 0.25, 0.20, 0.10, and 0.05 mg/kg of ZnO
NPs via the tail vein. After injection, symptoms and mortality were
observed.
Kinetic study
Based on LD50, a dose of 0.2 mg/kg of ZnO NPs was used in
this study. Six mice were used for each time point (5, 15, 30, and
60 min), and an additional group (n=24) for each time point (5, 15,
30, and 60 min) received an equivalent volume of distilled water
as a control. These mice received a single intravenous dose via
the tail vein and were sacrificed at the due time point. Blood and
tissues (lung, liver, kidney, and spleen) were collected and stored
at -20 until the Zn assay.
Tissue accumulation study
For this study, 6 mice were used for each time point (1, 3, and
6 days), and an additional group (n=18) for each time point (1, 3,
and 6 days)received an equivalent volume of distilled water as a
control. These mice received a single intravenous dose (0.05, 0.2
mg/kg) via the tail vein and were sacrificed at the due time
point. Blood and tissues (lung, liver, kidney, and spleen) were
collected and stored at -20 until the Zn assay.
Pathological examination
Tissue samples (liver, kidney, lung, and spleen) harvested at
each time point (1 h, 1 day, 3 days, and 6 days) following a single
intravenous dose (0.05, 0.2 mg/kg) were fixed in 10% formalin for
routine histologic processing. Paraffin sections were stained with
hematoxylin and eosin for pathological examination. A control
mouse was also examined in the same manner.
8-OHdG analysis
The concentrations of 8-OHdG in urine samples were meas-
ured using a competitive immunochromatography automatic ana-
lyzer (ICR-001, Techno Medica Co., Ltd., Yokohama, Japan),
which can measure both 8-OHdG and creatinine. The collected
sample was diluted 9-fold with distilled water, and 100 μl of urine
was placed into each inlet. The level of 8-OHdG in urine was ex-
pressed as ng/mg creatinine.
Zn assay
Zn in whole blood (200 μl) and homogenized tissue samples
were extracted by 0.01 M nitric acid (10 ml) by shaking overnight.
The samples were centrifuged at 14,000 rpm for 15 min at 4, and
the supernatant was subjected to Zn analysis by Metallo Assay Zinc
LS (AKJ Global Technology Co., Ltd., Chiba, Japan). Dissociated
Zn ions give a red-colored complex with 5-Br-PAPS (as chelator).
The intensity of the colored complex is proportional to the Zn con-
centration in the sample, and the concentration of Zn in the sample
is in turn determined by observation of the absorbance at 560 nm
using microtiter -plate reader (Sunrise Rainbow thermo RC-R,
Tecan Japan Co., Ltd., Japan). Absorbance at 700 nm was used for
correction. The coefficients of variation for intra- and inter -day pre-
cision were less than 5% and 9%, respectively.
Statistical analysis
The data were expressed as the meanstandard deviation. The
factorial measure ANOVA was used to compare the Zn concentra-
tion and 8-OHdG concentration among groups with the program
SPSS IBM 19 (IBM, Armonk, New York, USA). Differences in
groups were analyzed using the Dunnet test.
RESULTS
LD50
To obtain the LD50 in ICR mice, 500, 50, 5, 0.5, 0.4, 0.38, 0.36,
0.34, 0.33, 0.25, 0.20, 0.10, and 0.05 mg/kg of ZnO were exposed
to ICR mice via the tail vein. The LD50 in ICR mice was calculated
to be 0.3 mg/kg.
Blood kinetics
Based on the LD50, a dose of 0.2 mg/kg of ZnO NPs were used
in this study. In the present study, the data of blood presented as
increased Zn level after subtraction of the Zn level in the control
group. The time-course change in the blood Zn levels following
intravenous injection is shown in Fig. 1. The blood Zn concen-
tration peaked at 5 min and rapidly decreased after 15 min, then
changed moderately at the next time point. During the experiment,
no mortality was observed and marked hemolysis was not observed
in control in groups.
Short-term tissue distribution of ZnO
The short- term tissue distribution of ZnO was investigated at
4 time points (5 min, 15 min, 30 min, and 1 h) following intrave-
nous injection of ZnO NPs (0.2 mg/kg) (Fig. 2). In general, an
intravenously injected substance is first distributed in the lungs
and then distributed to whole body via blood circulation. The level
in the liver (Fig. 2A) and the lung (Fig. 2C) peaked at 5 min, and
that in the kidney (Fig. 2B) and spleen (Fig. 2D) peaked at 15 min.
The liver showed the lowest concentration among 4 tissues (Fig.
2A), and the kidney level rapidly decreased after 15 min to the
same level as the control group (Fig. 2B).
Long-term tissue distribution of ZnO
The long-term tissue accumulation of ZnO NPs were evaluated
at 3 time points (1 day, 3 days, and 6 days) following intravenous
injection of ZnO NPs (0.05 mg/kg, 0.2 mg/kg) (Fig. 3). To inves-
tigate the dose-dependent effect of ZnO NPs, these two doses were
investigated. At a dose of 0.05 mg/kg, only kidney levels at 1 day
showed significantly higher levels than those of the control group
(Fig. 3A). At a dose of 0.2 mg/kg, the spleen showed a significantly
Fig. 1. Time-course change in blood Zn levels following intravenous
administration (0.2 mg/kg) in mice. The data presented as increased
Zn levels after subtraction of the Zn level in the control group. Data
express meanS.D. (n=6) but the S.D. is within each symbol.
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higher Zn level at 1 day than that of the control group (Fig. 3B).
Within 3 time points, Zn concentration in the spleen was gradually
decreased. In contrast, the liver showed a significantly higher Zn
level than that of the control group at 6 days after the 0.2 mg/kg
dose. In the present study, dose-dependent distribution was not
observed.
8-OHdG analysis
Fig. 4 shows the 8-OHdG concentration in urine at several time
points (1 day, 3 days, and 6 days). The highest concentration was
observed at 1 day and gradually decreased at 6 days. A dose-de-
pendent effect was observed.
Pathological examination
Fig. 5 shows the time-course pathological findings for the lung,
liver, kidney, and spleen of mice dosed with ZnO NPs. Hepatic
sinusoid was partly dilated in mice at 1 day following intravenously
administered 0.2 mg/kg dose of ZnO NPs. Destruction and dilation
of the alveolar wall, which suggests pulmonary emphysema, was
observed in mice at 3 days after the 0.2 mg/kg dose and at 6 days
after the 0.05 mg/kg dose. No pathological change was observed
in the kidney or spleen. In the present study, pathological findings
were not correlated to Zn levels in tissue.
Fig. 2. Short - term tissue distribution of Zn following intravenous administration of a 0.2 mg/kg dose of ZnO NPs in mice : Liver (A), Kidney (B),
Lung (C), and Spleen (D). Data express meanS.D. (n=6). *, p0.05 ; **, p0.01 when compared between control groups (ANOVA, Dunnet test).
Fig. 3. Long-term tissue distribution of Zn following single intravenous administration of a 0.05 mg/kg dose (A) and a 0.2 mg/kg dose (B) of
ZnO NPs in mice. Data express meanS.D. (n=6). *, p0.05 ; ** p0.01 when compared between control groups (ANOVA, Dunnet test).
Fig. 4. Time-course variation in concentrations of 8 -OHdG in the urine of mice after single intravenous administration of ZnO NPs (0.05 mg/kg
0.2 mg/kg). Data express meanS.D. (n=6). *, p0.05 when compared between control groups (ANOVA, Dunnet test).
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DISCUSSION
ZnO NPs are widely used in commercial products such as semi-
conductors, zinc oxide ointments, baby powder, and sunscreen.
Because Zn is an essential element, biological and medical appli-
cation is expected. We consider the medical application of ZnO for
bio- imaging applications such as cancer diagnosis, and it is im-
portant to evaluate the toxicity before medical application. Several
previous studies in vivo have shown the toxicity of ZnO NPs. The
present study investigated the tissue distribution and accumulation
of intravenously administered ZnO NPs. Following injection, a rapid
decline in blood ZnO concentration was observed within 30 min
following injection (Fig. 1) : ZnO NPs were rapidly distributed to
organs. The present study indicated that ZnO NPs were mainly
accumulated in the lungs and spleen within 60 min after injection
(Fig. 2). The Zn level in the kidney peaked at 15 min and rapidly
decreased to a normal level at 30 min.
In the long-term tissue distribution study, the liver showed a
peak concentration at 6 days (Fig. 3B), and the spleen peaked at 1
day (Fig. 3B). Accumulation in the liver and spleen following in-
travenous injection of NPs such as silica, titanium dioxide, quan-
tum dots, gold, and silver, have been reported by previous studies
Fig. 5. The histopathological changes in the liver, kidney, lungs, and spleen (HE, 100x).
J. Fujihara, et al. Intravenous injection of ZnO dispersion NPs48
(16-19). Xie et al. have revealed that the TiO2 NPs were taken up
mainly by liver and spleen endocytosis, and they were also detected
in phagosomes (18). Macrophages, involved in the uptake and me-
tabolism of foreign molecules and particles, are located primarily
in the liver, spleen, lungs, and bone marrow (20). When NPs are
administered intravenously, various serum proteins bind to the sur-
face of the NPs, which are recognized by the scavenger receptors
on the macrophage cell surface and internalized, leading to a sig-
nificant loss of NPs from circulation (21). In the present study, the
Zn level in the liver was relatively low. This may be due to the dif-
ference in particle size, and the small -particle content may be low
in the present study. Lankveld et al. have reported that the 20 nm
Ag particles mainly distributed to the liver, whereas the larger par-
ticles mainly distributed to the spleen (17). In contrast, a previous
study has shown that the kidney, liver, and lungs would be pos-
sible target organs following single oral ZnO NPs administration
(22). The difference in tissue distribution is likely due to the ioni-
zation properties of ZnO : ZnO is soluble in acidic conditions and
readily dissolves under gastric conditions. A pathological change
was only observed in the lungs (pulmonary emphysema) and liver
(hepatic sinusoid) dilation (Fig. 5). This may be due to the higher
retention of ZnO in the lungs (Figs. 2 and 3).
The toxicity of ZnO NPs have been shown to be related to oxi-
dative stress, lipid peroxidation, cell membrane leakage, and oxi-
dative DNA damage in vitro (13, 23). Previous studies have shown
that ZnO NPs have cytotoxicity via Zn2+ release (24, 25). Gener-
ally, ZnO NPs are poorly water soluble but easily release Zn2+
into a culture medium. 8-OHdG is one of the major products of re-
active oxygen species (ROS)- induced DNA damage (26). It is
widely used as an important biomarker of oxidative DNA damage
(27). In the present study, 8-OHdG in urine at 3 time points (1
day, 3 days, and 6 days) was evaluated (Fig. 4). 8 -OHdG levels
peaked at 1 day and decreased to a normal level, and the level was
dose dependent. This indicates that ZnO NPs cause oxidative stress
by generating ROS. However, the levels were not remarkably high
when compared to the spleen and lungs : Zn2+ release might be
smaller by intravenous injection when compared to oral admini-
stration because of phagocytosis. A previous study has shown that
silica NPs generate ROS, and the generated ROS may trigger pro-
inflammatory responses both in vivo and in vitro (28). This has not
been confirmed with regard to ZnO NPs, and we are planning to
investigate the pro- inflammatory response relevance in ZnO NPs
toxicities. Further study is needed to evaluate the toxicological ef-
fect of ZnO NPs.
CONCLUSION
In this study, the blood kinetics and tissue distribution of a toxic
dose of ZnO NPs were first investigated following intravenous expo-
sure, and 8-OHdG was evaluated in the urine of ZnO NP-adminis-
tered mice. Following injection, ZnO NPs were rapidly removed
from the blood and distributed to various organs. Tissue distribu-
tion and pathological study showed that the spleen, liver, and lungs
are target organs for ZnO NPs. A dose-dependent increase in 8-
OHdG was observed in ZnO NP-treated mice. These results pro-
vide information on kinetic and target organs following intravenous
ZnO injection.
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